Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.

Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT.

Mol Cancer Ther. 2008 Jul;7(7):1846-50. doi: 10.1158/1535-7163.MCT-08-0168.

2.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
3.
4.

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.

Montemurro F, Valabrega G, Aglietta M.

Expert Opin Biol Ther. 2007 Feb;7(2):257-68. Review.

PMID:
17250463
5.

Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Friedecky D, Hajduch M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Dec;154(4):281-8. Review.

6.

Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

Ito Y, Tokudome N, Sugihara T, Takahashi S, Hatake K.

Breast Cancer. 2007;14(2):156-62. Review.

7.

Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.

Paul B, Trovato JA, Thompson J.

Am J Health Syst Pharm. 2008 Sep 15;65(18):1703-10. doi: 10.2146/ajhp070646. Review.

PMID:
18768996
8.

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

Johnston SR, Leary A.

Drugs Today (Barc). 2006 Jul;42(7):441-53. Review.

PMID:
16894399
9.

Targeting the HER/EGFR/ErbB family to prevent breast cancer.

Howe LR, Brown PH.

Cancer Prev Res (Phila). 2011 Aug;4(8):1149-57. doi: 10.1158/1940-6207.CAPR-11-0334. Review.

10.

Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.

Vogel C, Chan A, Gril B, Kim SB, Kurebayashi J, Liu L, Lu YS, Moon H.

Jpn J Clin Oncol. 2010 Nov;40(11):999-1013. doi: 10.1093/jjco/hyq084. Epub 2010 Jun 11. Review.

11.

Hormonally up-regulated neu-associated kinase: A novel target for breast cancer progression.

Zambrano JN, Neely BA, Yeh ES.

Pharmacol Res. 2017 May;119:188-194. doi: 10.1016/j.phrs.2017.02.007. Epub 2017 Feb 9. Review.

PMID:
28189783
12.

Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

Segovia-Mendoza M, González-González ME, Barrera D, Díaz L, García-Becerra R.

Am J Cancer Res. 2015 Aug 15;5(9):2531-61. eCollection 2015. Review.

13.

EGFR signaling in breast cancer: bad to the bone.

Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese DJ 2nd.

Semin Cell Dev Biol. 2010 Dec;21(9):951-60. doi: 10.1016/j.semcdb.2010.08.009. Epub 2010 Sep 9. Review.

14.

The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI.

Exp Mol Pathol. 2009 Aug;87(1):1-11. doi: 10.1016/j.yexmp.2009.05.001. Epub 2009 May 18. Review.

15.

Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.

Shi H, Zhang W, Zhi Q, Jiang M.

Tumour Biol. 2016 Oct 10. [Epub ahead of print] Review.

PMID:
27726101
16.

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.

Carney WP.

Expert Rev Mol Diagn. 2007 May;7(3):309-19. Review.

PMID:
17489737
17.

Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents.

Qiao J, Xue S, Pu F, White N, Jiang J, Liu ZR, Yang JJ.

J Biol Inorg Chem. 2014 Feb;19(2):259-70. doi: 10.1007/s00775-013-1076-3. Epub 2013 Dec 24. Review.

18.

EGFR may couple moderate alcohol consumption to increased breast cancer risk.

Mill CP, Chester JA, Riese DJ 2nd.

Breast Cancer (Dove Med Press). 2009 Oct 5;1:31-8. Review.

Supplemental Content

Support Center